Abstract
The production of viral vaccines, one of the most relevant classes of products within pharmaceutical biotechnology due to their positive impact on quality of life and the reduction of costs for national health systems, can be done through multiple platforms, such as through virus-like particles (VLP). Through this alternative, a protective immune response is generated with low doses. Cons…